Dasatinib side effects and contraindications

Dasatinib (Dasatinib) is a kinase inhibitor that blocks proteins that signal certain cancer cells to divide. It is used to treat Philadelphia chromosome-positive acute lymphoblastic leukemia (refractory to previous treatment or failure of treatment) and chronic, accelerated or bone marrow or lymphoblastic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Resistance or intolerance to previous treatments such as imatinib.

Common side effects of dasatinib include headache, nausea, diarrhea, fatigue, loss of appetite, and musculoskeletal pain. In addition, it may cause blood problems such as thrombocytopenia, anemia, and leukopenia. Some patients may also experience allergic reactions such as rash, edema, and difficulty breathing. It's important to note that the severity and frequency of these side effects may vary from individual to individual.

In addition, the use of dasatinib is contraindicated in the following situations: patients who are allergic to dasatinib or similar drugs; pregnant or breastfeeding women. Dasatinib may cause damage to the fetus and should be avoided during pregnancy or breastfeeding. In patients with serious heart problems, such as arrhythmia, heart failure, etc., dasatinib may aggravate heart problems, so its use should be avoided in these cases; in patients with severe liver or kidney dysfunction, the metabolism and excretion of dasatinib is mainly completed through the liver and kidneys. If the function of these organs is damaged, the drug may accumulate and cause adverse reactions.

In summary, dasatinib is an effective treatment for patients with chronic myelogenous leukemia and certain acute lymphoblastic leukemias. However, side effects need to be closely monitored during use and whether it is suitable for use based on the patient's specific situation.